用于治疗遗传性血管性水肿、糖尿病性黄斑水肿和糖尿病性视网膜病变的新型血浆激肽释放酶抑制剂
Novel Plasma Kallikrein Inhibitors for Treating Hereditary Angioedema, Diabetic Macular Edema, and Diabetic Retinopathy.
作者信息
Sabnis Ram W
机构信息
Smith, Gambrell & Russell LLP, 1105 W. Peachtree Street NE, Suite 1000, Atlanta, Georgia 30309, United States.
出版信息
ACS Med Chem Lett. 2023 Oct 19;14(11):1491-1492. doi: 10.1021/acsmedchemlett.3c00441. eCollection 2023 Nov 9.
Abstract
Provided herein are novel plasma kallikrein inhibitors, pharmaceutical compositions, use of such compounds in treating hereditary angioedema, diabetic macular edema, and diabetic retinopathy, and processes for preparing such compounds.
摘要
本文提供了新型血浆激肽释放酶抑制剂、药物组合物、此类化合物在治疗遗传性血管性水肿、糖尿病性黄斑水肿和糖尿病性视网膜病变中的用途，以及制备此类化合物的方法。
相似文献
1
Novel Plasma Kallikrein Inhibitors for Treating Hereditary Angioedema, Diabetic Macular Edema, and Diabetic Retinopathy.用于治疗遗传性血管性水肿、糖尿病性黄斑水肿和糖尿病性视网膜病变的新型血浆激肽释放酶抑制剂
ACS Med Chem Lett. 2023 Oct 19;14(11):1491-1492. doi: 10.1021/acsmedchemlett.3c00441. eCollection 2023 Nov 9.
2
Novel Plasma Kallikrein Inhibitors for Treating Hereditary Angioedema, Diabetic Macular Edema, and Diabetic Retinopathy.用于治疗遗传性血管性水肿、糖尿病性黄斑水肿和糖尿病性视网膜病变的新型血浆激肽释放酶抑制剂
ACS Med Chem Lett. 2022 Mar 4;13(4):528-529. doi: 10.1021/acsmedchemlett.2c00085. eCollection 2022 Apr 14.
3
Novel Plasma Kallikrein Inhibitors for Treating Hereditary Angioedema, Diabetic Macular Edema, and Diabetic Retinopathy.用于治疗遗传性血管性水肿、糖尿病性黄斑水肿和糖尿病性视网膜病变的新型血浆激肽释放酶抑制剂
ACS Med Chem Lett. 2022 May 13;13(6):883-884. doi: 10.1021/acsmedchemlett.2c00193. eCollection 2022 Jun 9.
4
Novel Plasma Kallikrein Inhibitors for Treating Hereditary Angioedema, Diabetic Macular Edema, and Diabetic Retinopathy.用于治疗遗传性血管性水肿、糖尿病性黄斑水肿和糖尿病性视网膜病变的新型血浆激肽释放酶抑制剂。
ACS Med Chem Lett. 2022 Jul 29;13(8):1217-1218. doi: 10.1021/acsmedchemlett.2c00323. eCollection 2022 Aug 11.
5
Plasma Kallikrein Inhibitors as Potential Treatment for Diabetic Macular Edema, Retinal Vein Occlusion, Hereditary Angioedema and Other Related Diseases.血浆激肽释放酶抑制剂作为糖尿病性黄斑水肿、视网膜静脉阻塞、遗传性血管性水肿及其他相关疾病的潜在治疗方法。
ACS Med Chem Lett. 2023 Jan 17;14(2):129-130. doi: 10.1021/acsmedchemlett.2c00526. eCollection 2023 Feb 9.
6
Investigational plasma kallikrein inhibitors for the treatment of diabetic macular edema: an expert assessment.用于治疗糖尿病性黄斑水肿的研究性血浆激肽释放酶抑制剂：专家评估。
Expert Opin Investig Drugs. 2020 Mar;29(3):237-244. doi: 10.1080/13543784.2020.1723078. Epub 2020 Jan 31.
7
Stable and Long-Lasting, Novel Bicyclic Peptide Plasma Kallikrein Inhibitors for the Treatment of Diabetic Macular Edema.稳定长效新型双环肽血浆激肽释放酶抑制剂治疗糖尿病性黄斑水肿。
J Med Chem. 2018 Apr 12;61(7):2823-2836. doi: 10.1021/acs.jmedchem.7b01625. Epub 2018 Mar 15.
8
Recent advances in the discovery and development of drugs targeting the kallikrein-kinin system.靶向激肽释放酶-激肽系统的药物发现与开发的最新进展。
J Transl Med. 2024 Apr 26;22(1):388. doi: 10.1186/s12967-024-05216-5.
9
Plasma kallikrein and diabetic macular edema.血浆激肽释放酶与糖尿病性黄斑水肿。
Curr Diab Rep. 2010 Aug;10(4):270-5. doi: 10.1007/s11892-010-0127-1.
10
The Role of Plasma Kallikrein-Kinin Pathway in the Development of Diabetic Retinopathy: Pathophysiology and Therapeutic Approaches.血浆激肽释放酶-激肽途径在糖尿病视网膜病变发生发展中的作用：病理生理学及治疗方法
Semin Ophthalmol. 2016;31(1-2):19-24. doi: 10.3109/08820538.2015.1114829.
引用本文的文献
1
Novel Plasma Kallikrein Inhibitors for Treating Multiple Diseases.用于治疗多种疾病的新型血浆激肽释放酶抑制剂
ACS Med Chem Lett. 2024 Oct 28;15(11):1808-1809. doi: 10.1021/acsmedchemlett.4c00484. eCollection 2024 Nov 14.
本文引用的文献
1
Hereditary Angioedema.遗传性血管性水肿。
Immunol Allergy Clin North Am. 2023 Aug;43(3):533-552. doi: 10.1016/j.iac.2022.10.012.
2
Current challenges and future opportunities in patient-focused management of hereditary angioedema: A narrative review.遗传性血管性水肿以患者为中心管理中的当前挑战与未来机遇：一项叙述性综述
Clin Transl Allergy. 2023 May;13(5):e12243. doi: 10.1002/clt2.12243.
3
Biochemistry, molecular genetics, and clinical aspects of hereditary angioedema with and without C1 inhibitor deficiency.遗传性血管性水肿伴和不伴 C1 抑制剂缺乏症的生化、分子遗传学和临床方面。
Allergol Int. 2023 Jul;72(3):375-384. doi: 10.1016/j.alit.2023.04.004. Epub 2023 May 9.
4
Hereditary Angioedema: A Disease Often Misdiagnosed and Mistreated.遗传性血管性水肿：一种常被误诊和误治的疾病。
Prim Care. 2023 Jun;50(2):295-303. doi: 10.1016/j.pop.2022.11.005. Epub 2023 Feb 26.
5
A narrative review of recent literature of the quality of life in hereditary angioedema patients.一篇关于遗传性血管性水肿患者生活质量的近期文献综述。
World Allergy Organ J. 2023 Mar 20;16(3):100758. doi: 10.1016/j.waojou.2023.100758. eCollection 2023 Mar.
6
Frontiers in diabetic retinal disease.糖尿病视网膜病变的前沿。
J Diabetes Complications. 2023 Feb;37(2):108386. doi: 10.1016/j.jdiacomp.2022.108386. Epub 2022 Dec 21.
Zotero 插件